Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer
Preoperative Chemosensitivity Testing as Predictor of Treatment Benefit in Adjuvant Stage III Colon Cancer: PePiTA Trial
Sponsor: Jules Bordet Institute
A NA clinical study on Colon Cancer, this trial is completed. The trial is conducted by Jules Bordet Institute and has accumulated 10 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Sep 2023 — Jul 2024 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Jan 2023 — Sep 2023 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
▶ Show 5 earlier versions
-
Jan 2021 — Jan 2023 [monthly]
Active Not Recruiting NA
-
Dec 2018 — Jan 2021 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Dec 2018 [monthly]
Recruiting NA
-
Feb 2017 — Jun 2018 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Nov 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jules Bordet Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bouge, Belgium, Brussels, Belgium, Charleroi, Belgium, Edegem, Belgium, Ghent, Belgium, Kortrijk, Belgium, Liège, Belgium, Merksem, Belgium, Mons, Belgium, Namur, Belgium and 4 more location s